University of California, Los Angeles
Los Angeles, California, 90095, United States
NCT Number: NCT07092995
Freezing of gait - the inability to start or continue walking - is a particularly disabling problem in Parkinson's disease that has few treatment options. This project records human brain activity from deep brain stimulation (DBS) devices during walking and freezing of gait episodes to understand the pathophysiology of freezing of gait. Findings will lay the foundation for the development of new treatment strategies that address this disabling symptom.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Los Angeles, California, 90095, United States
The pathophysiology of FOG is poorly understood, likely contributing to disappointing results of novel neuromodulation strategies. The goal of this study is to identify electrophysiological mechanisms of FOG that can serve as biomarkers for novel neuromodulation strategies. Activity in the globus pallidus internus (GPi), the major output nucleus of the basal ganglia, is central to understanding basal ganglia contributions to gait impairment, as it provides insights into activity that downstream locomotor circuits read out from the basal ganglia. The project leverages a state-of-the-art multimodal brain/behavior recording platform and recent advances in sensing deep brain stimulation devices to record neural activity from the human GPi simultaneously with electroencephalography (EEG), motion capture and eye gaze during over-ground walking and FOG episodes in PD patients with and without FOG. To reliably elicit FOG episodes and improve external validity, the investigators implement a novel immersive virtual reality environment to recapitulate real-world scenarios that commonly trigger FOG. With these tools, the proposed studies will determine how gait-related neural oscillations in the beta (12-30 Hz) and theta/alpha (4-12 Hz) bands in the GPi and cortex relate to abnormal gait during continuous walking (Aim 1); the onset and recovery from FOG episodes (Aim 2); and the therapeutic benefits from external cues (Aim 3). This paves the way for multiple innovative neuromodulation strategies that (1) prevent FOG episodes by promoting normal or compensatory gait control during continuous walking and (2) ameliorate severity of FOG episodes by targeting signals associated with FOG onset and recovery. Additionally, it establishes a novel VR paradigm for future precision-medicine approaches to FOG therapeutic development.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Walking overground in immersive virtual reality (VR) environments that provoke freezing episodes
Walking overground with and without concomitant performance of secondary cognitive or motor task
Walking overground in immersive virtual reality (VR) environments that provoke freezing episodes with and without addition of visual and auditory cues.
Time frame: Day 1
Globus pallidus internus (GPi) spectral power change during walking versus standing rest.
Time frame: Day 2
Globus pallidus internus (GPi) spectral power changes from baseline time-locked to gait cycle events, freezing episodes, and voluntary stopping events
Time frame: Day 3
Globus pallidus internus (GPi) spectral power change during walking with versus without external cues.
University of California, Los Angeles
Other
Leveraging Invasive Recordings and Immersive Virtual Reality to Characterize Freezing of Gait Mechanisms in Parkinson Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06724029
Aneurysm, Aneurysms
Bergamo, BG, Italy
View Trial DetailsNCT06886178
Action Tremor, Dyskinesias
Nijmegen, Gelderland, Netherlands
View Trial DetailsNCT06816810
Inflammation, Nervous System Diseases
Ottawa, Ontario, Canada
View Trial DetailsNCT06772220
Basal Ganglia Diseases, Brain Diseases
Portland, Oregon, United States
View Trial Details